Skip to main content

Table 3 The clinical and radiomic characteristics of patients in the training and validation cohorts

From: Baseline MRI-based radiomics model assisted predicting disease progression in nasopharyngeal carcinoma patients with complete response after treatment

Characteristic

Training cohort(n = 119)

Validation cohort(n = 52)

P value

Age (mean ± SD, years)

43.34 ± 12.5

44.81 ± 13.1

0.49

Gender

0.44

 Male

95

38

 

 Female

24

14

 

Histology

0.79

 Differentiated Non-keratinising

62

26

 

 Undifferentiated

 Non-keratinising

57

26

 

T stage

0.13

 T1

17

6

 

 T2

21

10

 

 T3

40

26

 

 T4

41

10

 

N stage

0.11

 N0

10

2

 

 N1

41

14

 

 N2

53

22

 

 N3

15

14

 

Overall stage

0.71

 I

1

0

 

 II

14

5

 

 III

50

19

 

 IV

54

28

 

Treatment

0.24

 A

14

8

 

 B

56

28

 

 C

5

5

 

 D

44

11

 

EA-IgA

 Positive

38

15

0.82

 Negative

81

37

 

VCA-IgA

 Positive

42

33

1.00

 Negative

77

19

 

Smoking

1.00

 Yes

57

25

 

 No

62

27

 

 Variance_T1

7.67 ± 0.71

7.64 ± 0.70

0.77

 IQR_T1

4.34 ± 0.76

4.37 ± 0.69

0.81

 Skewness_T2

−1.79 ± 0.70

−1.96 ± 0.72

0.16

 Kurtosis_T1H

6.62 ± 2.29

6.71 ± 1.55

0.80

 HGLZE_T2H

2.87 ± 0.43

2.92 ± 0.39

0.45

 HGLZE_T1

3.03 ± 0.41

3.16 ± 0.42

0.06

 DV_T1

22.17 ± 2.16

22.51 ± 2.10

0.34

 Kurtosis_T1L

8.24 ± 3.82

7.69 ± 2.92

0.35

 LDLGLE_T1

145.67 ± 11.28

147.02 ± 11.15

0.47

 Kurtosis_T2

9.04 ± 9.04

8.18 ± 4.83

0.52

 HGLZE_T2L

2.55 ± 0.51

2.44 ± 0.46

0.19

 Minimum_T1

−1.84 ± 0.44

− 1.75 ± 0.42

0.22

 GLNU_T1

5.24 ± 2.51

5.52 ± 2.40

0.49

Prognosis

0.64

 Disease progression

51

25

 

 Non-disease progression

68

27

 
  1. Treatment: A-Radiotherapy, B-Chemotherapy + Radiotherapy, C-Targeted therapy + Radiotherapy, D-Concurrent Chemoradiotherapy + Targeted Therapy, E-Chemotherapy + Targeted Therapy; * indicates statistical significant difference